Download a patient enrollment for for the PROPEL™ sinus implant.
Sinus implants
PROPEL™ (mometasone furoate) sinus implant
<p>The PROPEL™ sinus implant maintains patency and locally delivers steroid to the sinus mucosa in patients 18 years and older following sinus surgery.</p>
Features
PROPEL™ sinus implants keep the sinuses open while releasing mometasone furoate (MF).
PROPEL™ sinus implants feature an innovative two-in-one mechanism that opens in the sinuses while delivering MF, a potent corticosteroid, directly where it is needed.2–4
- Self-expanding design that opens and supports the sinus cavity
- Delivers 370 mcg of MF over 30 days†
- Non-obstructive design allows for sinus mucociliary clearance and the delivery of topical rinses
- MF present in the sinus mucosal tissue for up to 60 days5
- Structural backbone bio-absorbs over approximately 30–45 days after placement as the sinus cavity heals
Mometasone furoate delivers a combination of potency and safety.
Drug characteristics comparison6–9
| Topical corticosteroid | Lipophilicity‡,6 | Potency (receptor affinity)†,7 | Systemic bioavailablity‡,8 |
|---|---|---|---|
| Dexamethasone | Very low (less than 1.0) | Very low (100) | High (76%) |
| Triamcinolone (Kenalog) | Low (1.0) | Low (233) | Medium (46%) |
| Budesonide | Low (1.6) | Intermediate (935) | Medium (34%) |
| Mometasone furoate | High (20.0) | High (2,300) | Very low (less than 1%) |
Optimal sinonasal drug characteristics7
Highly lipophilic
Readily absorbs into tissue
Targeted and potent
High glucocorticoid receptor affinity
Low systemic bioavailability
Minimize systemic effects
PROPEL™ sinus implants are clinically proven to maintain patency and improve patient outcomes following endoscopic sinus surgery by targeting inflammation, the underlying cause of chronic rhinosinusitis.
Resources
† Lipophilicity numbers normalized relative to triamcinolone acetonide.
‡ As measured by relative receptor binding affinity compared to dexamethasone, which is set to a value of 100. Higher values designate greater potency.
- Food and Drug Administration. Approval order. Accessed June 28, 2019.
- PROPEL™ instructions for use. Menlo Park, CA: Intersect ENT; 2020.
- PROPEL™ mini instructions for use. Menlo Park, CA: Intersect ENT; 2020.
- PROPEL™ contour instructions for use. Menlo Park, CA: Intersect ENT; 2020.
- Li PM, Downie D, Hwang PH. Controlled steroid delivery via bioabsorbable stent: safety and performance in a rabbit model. Am J Rhinol Allergy. 2009;23(6):591–596.
- Lemke T, Williams D, Roche V, Zito SW, eds. Foye’s Principles of Medicinal Chemistry. 6th ed. Balitmore, MD: Lippincott Williams & Wilkins; 2008.
- Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1(4):356–363.
- Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22(1):1–12.
- National Library of Medicine. PubChem. Dexamethasone. Accessed June 24, 2019.